BULLFROG AI HOLDINGS, INC. Share-based Payment Arrangement, Expense
BULLFROG AI HOLDINGS, INC. (BFRG) reported Share-based Payment Arrangement, Expense of $1.19 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-14
- BULLFROG AI HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $1.19K, a 99.33% decline year-over-year.
- BULLFROG AI HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $1.19K, a 99.60% decline year-over-year.
- BULLFROG AI HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $98.72K, a 53.93% decline year-over-year.
- BULLFROG AI HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $145.39K, a 27.87% decline year-over-year.
- BULLFROG AI HOLDINGS, INC. share-based payment arrangement, expense for fiscal 2025 was $722.30K, a 23.21% decline from fiscal 2024.
- BULLFROG AI HOLDINGS, INC. share-based payment arrangement, expense for fiscal 2024 was $940.64K, a 58.82% increase from fiscal 2023.
- BULLFROG AI HOLDINGS, INC. share-based payment arrangement, expense for fiscal 2023 was $592.27K.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.19K 10-Q · filed 2026-08-14 | $2.38K 10-Q · filed 2026-08-14 | $101.10K derived: sum of 3 quarters · filed 2026-08-14 | $246.49K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.19K 10-Q · filed 2026-05-14 | $99.91K derived: sum of 2 quarters · filed 2026-05-14 | $245.30K derived: sum of 3 quarters · filed 2026-05-14 | $423.20K derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | $98.72K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $244.11K derived: sum of 2 quarters · filed 2026-03-19 | $422.02K derived: sum of 3 quarters · filed 2026-03-19 | $722.30K 10-K · filed 2026-03-19 |
| 2025-09-30 | $145.39K 10-Q · filed 2025-11-14 | $323.29K derived: sum of 2 quarters · filed 2025-11-14 | $623.58K 10-Q · filed 2025-11-14 | $837.86K derived: sum of 4 quarters · filed 2026-03-19 |
| 2025-06-30 | $177.91K 10-Q · filed 2025-08-13 | $478.19K 10-Q · filed 2025-08-13 | $692.47K derived: sum of 3 quarters · filed 2026-03-19 | $894.04K derived: sum of 4 quarters · filed 2026-03-19 |
| 2025-03-31 | $300.29K 10-Q · filed 2025-05-13 | $514.57K derived: sum of 2 quarters · filed 2026-03-19 | $716.14K derived: sum of 3 quarters · filed 2026-03-19 | $907.91K derived: sum of 4 quarters · filed 2026-03-19 |
| 2024-12-31 | $214.28K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $415.85K derived: sum of 2 quarters · filed 2026-03-19 | $607.62K derived: sum of 3 quarters · filed 2026-03-19 | $940.64K 10-K · filed 2026-03-19 |
| 2024-09-30 | $201.57K 10-Q · filed 2025-11-14 | $393.34K derived: sum of 2 quarters · filed 2025-11-14 | $726.36K 10-Q · filed 2025-11-14 | $843.17K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $191.77K 10-Q · filed 2025-08-13 | $524.79K 10-Q · filed 2025-08-13 | $641.60K derived: sum of 3 quarters · filed 2025-08-13 | $758.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $333.02K 10-Q · filed 2025-05-13 | $449.82K derived: sum of 2 quarters · filed 2025-05-13 | $566.23K derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $116.80K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $233.21K derived: sum of 2 quarters · filed 2025-03-14 | $592.27K 10-K · filed 2025-03-14 | |
| 2023-09-30 | $116.41K 10-Q · filed 2024-11-08 | $475.46K 10-Q · filed 2024-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B |